Comparative effects of pravastatin and rosuvastatin on carbohydrate metabolism in an experimental diabetic rat model

1J. C. Pickup and G. Williams, Textbook of Diabetes, 3rd ed., Blackwell Science, Oxford 2003, pp. 103–114.Search in Google Scholar

2T. Tella, B. Masola and S. Mukaratirwa, The effect of Psidium guajava aqueous leaf extract on liver glycogen enzymes, hormone sensitive lipase and serum lipid profile in diabetic rats, Biomed. Pharmacother. 109 (2019) 2441–2446; https://doi.org/10.1016/j.biopha.2018.11.137Search in Google Scholar

3J. D. Colbert and J. A. Stone, Statin use and the risk of incident diabetes mellitus: a review of the literature, Can. J. Cardiol. 28(5) (2012) 581–589; https://doi.org/10.1016/j.cjca.2012.03.021Search in Google Scholar

4T. Yada, M. Nakata, T. Shiraishi and M. Kakei, Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca²⁺ signalling and insulin secretion due to blockade of L-type Ca²⁺ channels in rat islet beta-cells, Br. J. Pharmacol. 126(5) (1999) 1205–1213; https://doi.org/10.1038/sj.bjp.0702397Search in Google Scholar

5M. J. Ko, A. J. Jo, Y. J. Kim, S. H. Kang, S. Cho, S. Jo, C. Park, S. Yun, W. J. Lee and D. Park, Time- and dose-dependent association of statin use with risk of clinically relevant new-onset diabetes mellitus in primary prevention: A nationwide observational cohort study, J. Am. Heart Assoc. 8(8) (2019) e011320; https://doi.org/10.1161/JAHA.118.011320Search in Google Scholar

6Z. Zhou, A. J. Curtis, M. E. Ernst, J. Ryan, S. Zoungas, R. Wolfe, J. J. McNeil, A. M. Murray, C. M. Reid, E. K. Chowdhury, R. L. Woods, A. M. Tonkin and M. R. Nelson, Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults, Eur. J. Clin. Pharmacol. 78(3) (2022) 467–476; https://doi.org/10.1007/s00228-021-03239-1Search in Google Scholar

7K. K. Koh, P. C. Oh, I. Sakuma, Y. Lee, S. H. Han and E. K. Shin, Rosuvastatin dose-dependently improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hyper-cholesterolemic patients, Int. J. Cardiol. 15(223) (2016) 488–493; https://doi.org/10.1016/j.ij-card.2016.08.051Search in Google Scholar

8P. M. Ridker, E. Danielson, F. A. H. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, B. G. Nordestgaard, J. Shepherd, J. T. Willerson and R. J. Glynn (for JUPITER Study Group), Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N. Engl. J. Med. 359(21) (2008) 2195–2207; https://doi.org/10.1056/NEJMoa0807646Search in Google Scholar

9G. Danaei, L. A. Garcia Rodriguez, O. Fernandez Cantero and M. A Hernan, Statins and risk of diabetes: an analysis of electronic medical records to evaluate possible bias due to differential survival, Diabetes Care 36(5) (2013) 1236–1240; https://doi.org/10.2337/dc12-1756Search in Google Scholar

10K. L. Wang, C.-J. Liu, T.-F. Chao, C.-M. Huang, C.-H. Wu, S.-J. Chen, T.-J. Chen, S.-J. Lin and C.-E. Chiang, Statins, risk of diabetes, and implications on outcomes in the general population, J. Am. Coll. Cardiol. 60(14) (2012) 1231–1238; https://doi.org/10.1016/j.jacc.2012.05.019Search in Google Scholar

11N. Sattar, D. Preiss, H. M. Murray, P. Welsh, B. M. Buckley, A. J. M. de Craen, S. R. K. Seshasai, J. J. McMurray, D. J. Freeman, J. W. Jukema, P. W. Macfarlane, C. J. Packard, D. J. Stott, R. G. Westendorp, J. Shepherd, B. R. Davis, S. L. Pressel, R. Marchioli, R. M. Marfisi, A. P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekshus, T. R. Pedersen, T. J. Cook, A. M. Gotto, M. B. Clearfield, J. R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, K. K. Ray and I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet 375(9716) (2010) 735–742; https://doi.org/10.1016/S0140-6736(09)61965-6Search in Google Scholar

12D. J. Freeman, J. Norrie, N. Sattar, R. D. G. Neely, S. M. Cobbe, I. Ford, C. Isles, A. R. Lorimer, P. W. Macfarlane, J. H. McKillop, C. J. Packard, J. Shepherd and A. Gaw, Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland coronary prevention study, Circulation 103(3) (2001) 357–362; https://doi.org/10.1161/01.cir.103.3.357Search in Google Scholar

13S. Lim, I. Sakuma, M. J. Quon and K. K. Koh, Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality, Int. J. Cardiol. 167 (2013) 1696–1702; https://doi.org/10.1016/j.ijcard.2012.10.037Search in Google Scholar

14S. Parida, T. R. Swain, S. N. Routray and R. Maiti, Effect of atorvastatin on glycaemic parameters in normoglycaemic and prediabetic subjects: A prospective, panel study, J. Clin. Diagn. Res. 11(2) (2017) FC04-FC09; https://doi.org/10.7860/JCDR/2017/23741.9427Search in Google Scholar

15M. J. Crespo and J. Quidgley, Simvastatin, atorvastatin, and pravastatin equally improve the hemo-dynamic status of diabetic rats, World J. Diabetes 6(10) (2015) 1168–1178; https://doi.org/10.4239/wjd.v6.i10.1168Search in Google Scholar

16J. J. Min, B. S. Shin, J. H. Lee, Y. Jeon, D. K. Ryu, S. Kim and Y. H. Shin, Effects of pravastatin on type 1 diabetic rat heart with or without blood glycemic control, J. Diabetes Res. 28 (2018) Article ID 1067853 (9 pages); https://doi.org/10.1155/2018/1067853Search in Google Scholar

17N. Ozturk, N. Yaras, A. Ozmen and S. Ozdemir, Long-term administration of rosuvastatin prevents contractile and electrical remodelling of diabetic rat heart, J. Bioenerg. Biomembr. 45(4) (2013) 343–352; https://doi.org/10.1007/s10863-013-9514-zSearch in Google Scholar

18K. Tarhzaoui, P. Valensi, G. Leger, F. Cohen-Boulakia, R. Lestrade and A. Behar, Rosuvastatin positively changes nerve electrophysiology in diabetic rats, Diabetes Metab. Res. Rev. 25(3) (2009) 272–278; https://doi.org/10.1002/dmrr.920Search in Google Scholar

19D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher and R. C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia 28(7) (1985) 412–419; https://doi.org/10.1007/BF00280883Search in Google Scholar

20O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, Protein measurement with the Folin phenol reagent, J. Biol. Chem. 193(1) (1951) 265–275.Search in Google Scholar

21P. Subash Babu, S. Prabuseenivasan and S. Ignacimuthu, Cinnamaldehyde-a potential antidiabetic agent, Phytomedicine 14(1) (2007) 15–22; https://doi.org/10.1016/j.phymed.2006.11.005Search in Google Scholar

22D. Mondol, M. N. Islam, S. Biswas, P. Jodder, S. Sana, M. A. Saleh and M. R. Islam, Investigation of the synergistic effect of glimepiride and rosuvastatin on alloxan-induced diabetic rat, J. Diabetes Metab. Disord. 19(2) (2020) 1415–1422; https://doi.org/10.1007/s40200-020-00662-6Search in Google Scholar

23K. Gothandam, V. S. Ganesan, T. Ayyasamy and S. Ramalingam, Antioxidant potential of the aflavin ameliorates the activities of key enzymes of glucose metabolism in high fat diet and streptozotocin-induced diabetic rats, Redox Rep. 24(1) (2019) 41–50; https://doi.org/10.1080/13510002.2019.1624085Search in Google Scholar

24I. Dhananjayan, S. Kathiroli, S. Subramani and V. Veerasamy, Ameliorating effect of betanin, a natural chromoalkaloid by modulating hepatic carbohydrate metabolic enzyme activities and glycogen content in streptozotocin-nicotinamide induced experimental rats, Biomed. Pharmacother. 88 (2017) 1069–1079; https://doi.org/10.1016/j.biopha.2017.01.146Search in Google Scholar

25N. Abboud and R. Makhous, The effect of some statins on glucose blood levels in experimental animals, Res. J. Pharm. Technol. 15(6) (2022) 2661–2666; https://doi.org/10.52711/0974-360X.2022.00445Search in Google Scholar

26Y. Yu, K. Ohmori, Y. Chen, C. Sato, H. Kiyomoto, K. Shinomiya, H. Takeuchi, K. Mizushige and M. Kohno, Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model, J. Am. Coll. Cardiol. 44(4) (2004) 904–913; https://doi.org/10.1016/j.jacc.2004.04.050Search in Google Scholar

27T. Takagi, M. Matsuda, M. Abe, H. Kobayashi, A. Fukuhara, R. Komuro, S. Kihara, M. J. Caslake, A. McMahon, J. Shepherd, T. Funahashi and I. Shimomura, Effect of pravastatin on the development of diabetes and adiponectin production, Atherosclerosis 196(1) (2008) 114–121; https://doi.org/10.1016/j.atherosclerosis.2007.02.013Search in Google Scholar

28S. Sugiyama, H. Fukushima, K. Kugiyama, H. Maruyoshi, S. Kojima, T. Funahashi, T. Sakamoto, Y. Horibata, K. Watanabe, H. Koga, K. Sugamura, F. Otsuka, I. Shimomura and H. Ogawa, Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease, Atherosclerosis 194(2) (2007) E43-E51; https://doi.org/10.1016/j.atherosclerosis.2006.08.023Search in Google Scholar

29A. Keech, D. Colquhoun, J. Best, A. Kirby, R. J. Simes, D. Hunt, W. Hague, E. Beller, M. Arulchelvam, J. Baker and A. Tonkin (for LIPID study group), Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial, Diabetes Care 26(10) (2003) 2713–2721; https://doi.org/10.2337/diacare.26.10.2713Search in Google Scholar

30J. Shepherd, G. J. Blauw, M. B. Murphy, E. L. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, J. W. Jukema, A. M. Kamper, P. W. Macfarlane, A. E. Meinders, J. Norrie, C. J. Packard, I. J. Perry, D. J. Stott, B. J. Sweeney, C. Twomey and R. G. Westendorp (for PROSPER study group), PRO-spective study of pravastatin in the elderly at risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet 360(9346) (2002) 1623–1630; https://doi.org/10.1016/s0140-6736(02)11600-x.9Search in Google Scholar

31S. Simsek, C. G. Schalkwijk and B. H. Wolffenbuttel, Effects of rosuvastatin and atorvastatin on glycaemic control in type 2 diabetes – the CORALL study, Diabet Med. 29(5) (2012) 628–631; https://doi.org/10.1111/j.1464-5491.2011.03553.xSearch in Google Scholar

32T. Katabami, M. Murakami, S. Kobayashi, T. Matsui, M. Ujihara, S. Takagi, M. Higa, T. Ichijo, A. Ohta and Y. Tanaka, Efficacy of low-dose rosuvastatin in patients with type 2 diabetes and hypo high-density lipoprotein cholesterolaemia, J. Int. Med. Res. 42(2) (2014) 457–467; https://doi.org/10.1177/0300060513507648Search in Google Scholar

33D. Xilifu, Z. Tuerxun, B. Nuermaimaiti, A. Aili, N. Rehemu, H. Sun and X. Zhang, Effects of rosuvastatin on serum glucose and insulin in hyperuricemic rats, BMC Pharmacol. Toxicol. 23(1) (2022) Article ID 66 (10 pages); https://doi.org/10.1186/s40360-022-00595-1Search in Google Scholar

34M. S. Kostapanos, H. J. Milionis, A. D. Agouridis, C. V. Rizos and M. S. Elisaf, Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose, Int. J. Clin. Pract. 63 (2009) 1308–1313; https://doi.org/10.1111/j.1742-1241.2009.02101.xSearch in Google Scholar

35D. Preiss, S. R. Seshasai, P. Welsh, S. A. Murphy, J. E. Ho, D. D. Waters, D. A. DeMicco, P. Barter, C. P. Cannon, M. S. Sabatine, E. Braunwald, J. J. Kastelein, J. A. de Lemos, M. A. Blazing, T. R. Pedersen, M. J. Tikkanen, N. Sattar and K. K. Ray, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA 305(24) (2011) 2556–2564; https://doi.org/10.1001/jama.2011.860Search in Google Scholar

36K. K. Koh, M. J. Quon, S. H. Han, Y. Lee, S. J. Kim, J. B. Park and E. K. Shin, Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients, Atherosclerosis 204(2) (2009) 483–490; https://doi.org/10.1016/j.atherosclerosis.2008.09.021Search in Google Scholar

37J. H. Kim, M. Lee, J. Shin, S. Lee, J. Lee, S. J. You, K. H. Yoon and S. A. Chang, Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus, Atherosclerosis 227(2) (2013) 355–359; https://doi.org/10.1016/j.atherosclerosis.2013.01.045Search in Google Scholar

38N. Thongtang, M. Ai, S. Otokozawa, T. V. Himbergen, B. F. Asztalos, K. Nakajima, E. Stein, P. H. Jones and E. J. Schaefer, Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation, Am. J. Cardiol. 107(3) (2011) 387–392; https://doi.org/10.1016/j.amjcard.2010.09.031Search in Google Scholar

39K. S. Shali, N. P. P. Soumya, S. Mondal and S. Mini, Hepatoprotective effect of morin via regulating the oxidative stress and carbohydrate metabolism in STZ induced diabetic rats, Bioact. Compd. Health Dis. 5(3) (2022) 53–66; https://doi.org/10.31989/bchd.v5i2.893Search in Google Scholar

40E. K. Ainscow, C. Zhao and G. A. Rutter, Acute overexpression of lactate dehydrogenase-A perturbs beta-cell mitochondrial metabolism and insulin secretion, Diabetes 49(7) (2000) 1149–1155; https://doi.org/10.2337/diabetes.49.7.1149Search in Google Scholar

41R. Chen, M. Meseck, R. C. McEvoy and S. L. Woo, Glucose-stimulated and self-limiting insulin production by glucose 6-phosphatase promoter driven insulin expression in hepatoma cells, Gene Ther. 7(21) (2000) 1802–1809; https://doi.org/10.1038/sj.gt.3301306Search in Google Scholar

42D. Gupta, J. Raju, J. Prakash R. and N. Z. Baquer, Change in the lipid profile, lipogenic and related enzymes in the livers of experimental diabetic rats: effect of insulin and vanadate, Diabetes Res. Clin. Pract. 46(1) (1999) 1–7; https://doi.org/10.1016/s0168-8227(99)00067-4Search in Google Scholar

43K. Aoki, T. Saito, S. Satoh, K. Mukasa, M. Kaneshiro, S. Kawasaki, A. Okamura and H. Sekihara, Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone, Diabetes 48(8) (1999) 1579–1585; https://doi.org/10.2337/diabetes.48.8.1579Search in Google Scholar

44Y. Xu, B. W. Osborne and R. C. Stanton, Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex, Am. J. Physiol. Renal Physiol. 289(5) (2005) F1040-F1047; https://doi.org/10.1152/ajprenal.00076.2005Search in Google Scholar

45B. M. McDermott, P. R. Flatt and J. J. Strain, Effects of copper deficiency and experimental diabetes on tissue antioxidant enzyme levels in rats, Ann. Nutr. Metab. 38(5) (1994) 263–269; https://doi.org/10.1159/000177820Search in Google Scholar